TWD 138.5
(-1.07%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 138 Thousand TWD | -90.19% |
2022 | 1.4 Million TWD | 417.28% |
2021 | 272 Thousand TWD | -55.56% |
2020 | 612 Thousand TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 121 Thousand TWD | 0.0% |
2024 Q2 | 104 Thousand TWD | 0.0% |
2023 Q3 | 421 Thousand TWD | -44.09% |
2023 FY | 138 Thousand TWD | -90.19% |
2023 Q1 | 1.08 Million TWD | 0.0% |
2023 Q2 | 753 Thousand TWD | -30.41% |
2023 Q4 | 138 Thousand TWD | -67.22% |
2022 Q4 | - TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Allied Biotech Corporation | 72.02 Million TWD | 99.808% |
GeneFerm Biotechnology Co., Ltd. | 76.14 Million TWD | 99.819% |
Easywell Biomedicals, Inc. | 330.44 Million TWD | 99.958% |
TTY Biopharm Company Limited | 403.04 Million TWD | 99.966% |
Synmosa Biopharma Corporation | 1.45 Billion TWD | 99.991% |
Orient EuroPharma Co., Ltd. | 2.2 Billion TWD | 99.994% |
Center Laboratories, Inc. | 4.42 Billion TWD | 99.997% |
Tien Liang BioTech Co., Ltd. | 377 Thousand TWD | 63.395% |
Orient Pharma Co., Ltd. | 323.73 Million TWD | 99.957% |
InnoPharmax Inc. | 5.38 Million TWD | 97.438% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 100.83 Million TWD | 99.863% |
Excelsior Biopharma Inc. | 300.25 Million TWD | 99.954% |
DV Biomed Co., Ltd. | 315.74 Million TWD | 99.956% |
Foresee Pharmaceuticals Co., Ltd. | 13.11 Million TWD | 98.948% |
Handa Pharmaceuticals, Inc. | 7.67 Million TWD | 98.201% |
UniPharma Co., Ltd. | - TWD | -Infinity% |
Anxo Pharmaceutical Co., Ltd. | 499.69 Million TWD | 99.972% |
Winston Medical Supply Co., Ltd. | 56.05 Million TWD | 99.754% |
Mercury Biopharmaceutical Corporation | 41.66 Million TWD | 99.669% |
Bioray Biotech Co., Ltd | 65.65 Million TWD | 99.79% |
TSH Biopharm Corporation Limited | - TWD | -Infinity% |